Sinovac CEO Weidong Yin On China’s Evolving Vaccine Market: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Sinovac Biotech CEO Weidong Yin recently spoke with PharmAsia News' Shanghai bureau about the Chinese vaccine market and the impact of current government policies on vaccine makers. Sinovac was established in April 2001 as a result of a joint venture between Sino Pharma, Shenzhen Kexing and Tangshan Yian. The Beijing-based company manufactured its first hepatitis A vaccine and sold its first dose in 2002. In December 2004, it was listed on the American Stock Exchange.
You may also be interested in...
Vaccine Market Will Lead Pharmaceutical Industry In China And Globally, Frost & Sullivan Predicts
SHANGHAI - The compound annual growth rate of the global pharmaceutical industry is expected to be around 4-5 percent in the next seven years, while the worldwide vaccine market grows faster, at a CAGR of 14-15 percent, the global business research and consulting firm Frost & Sullivan predicted
Vaccine Market Will Lead Pharmaceutical Industry In China And Globally, Frost & Sullivan Predicts
SHANGHAI - The compound annual growth rate of the global pharmaceutical industry is expected to be around 4-5 percent in the next seven years, while the worldwide vaccine market grows faster, at a CAGR of 14-15 percent, the global business research and consulting firm Frost & Sullivan predicted
Sinovac Awarded High-Tech Status, Which Brings Lower Taxes And Other Government Benefits
SHANGHAI - Sinovac Biotech has been granted high-tech enterprise status by three government departments and will get a lower tax rate, at 15 percent, from the standard rate of 25 percent, from 2008 to 2010, the company announced March 9